S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Proceedings Article
Computing performance measures for inpatient glucose management.
TL;DR: This work developed an application accessible over the internet that facilitates computation of candidate measures of performance in glycemic control, but these require analysis of large glucose datasets, a cumbersome task for individual institutions.
Journal ArticleDOI
The effect of dapagliflozin across the spectrum of baseline risk: a post-hoc analysis of DAPA-HF
Kieran F. Docherty,P.S Jhund,Olof Bengtsson,David L. DeMets,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,AM Langkilde,Daniel Lindholm,F.A Martinez,P. Ponikowski,Marc S. Sabatine,Mikaela Sjöstrand,Scott D. Solomon,Jjv McMurray +14 more
TL;DR: Treatment with dapagliflozin, compared to placebo, reduced the risk of cardiovascular death or worsening heart failure, irrespective of baseline risk as measured by the MAGGIC risk score.
Journal ArticleDOI
28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME
Subodh Verma,Lawrence A. Leiter,Abhinav Sharma,Bernard Zinman,Michaela Mattheus,David Fitchett,Jyothis T. George,Anne Pernille Ofstad,Christoph Wanner,Silvio E. Inzucchi +9 more
TL;DR: The benefit of empagliflozin in reducing the risk of HHF, CV death/HHF and CV death emerged within weeks after treatment initiation in EMPA-REG OUTCOME, and the earliest effect appears to be on HHF.
Journal ArticleDOI
Pioglitazone and cardiovascular risk reduction: time for a second look?
TL;DR: The findings of the recent Insulin Resistance Intervention after Stroke trial that demonstrated a beneficial effect of pioglitazone on CV outcomes in stroke patients with insulin resistance are focused on.
Journal ArticleDOI